BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

H. Lundbeck A/S 

Ottiliavej 9

Valby  Copenhagen  DK-2500  Denmark
Phone: 45-3630-1311 Fax: 45 3630 1940


SEARCH JOBS

View Clinical Trials from BioPharm Insight





Collaborations

Forest Laboratories, Inc.  Forest's partner for many of the drug compounds that we develop, manufacture and market in the U.S. for central nervous system disorders, including Lexapro.





 Company News
H. Lundbeck A/S (LUN.CO) Will Halt Studies Into Vampire Bat Saliva Drug 12/18/2014 9:26:03 AM
Ossianix Expands And Extends Its Research Collaboration With H. Lundbeck A/S (LUN.CO) On CNS Therapeutics 12/16/2014 10:52:35 AM
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S (LUN.CO) Release: U.S. FDA Accepts For Review Supplemental New Drug Application For Deltoid Administration Of Abilify Maintena® (Aripiprazole) Extended-Release Injectable Suspension 12/15/2014 10:13:44 AM
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO)’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting 12/11/2014 7:27:03 AM
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting 12/10/2014 10:29:43 AM
H. Lundbeck A/S (LUN.CO) Release: New Study: Art Therapy May Build Self-Esteem In People Living With Epilepsy 12/8/2014 10:27:38 AM
H. Lundbeck A/S (LUN.CO) Release: Five-Year Data From SABRIL® (Vigabatrin) Registry Presented At American Epilepsy Society Annual Meeting 12/8/2014 10:26:40 AM
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S (LUN.CO) Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia 11/3/2014 10:57:38 AM
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Submit New Drug Application In The US For Brexpiprazole For The Treatment Of Schizophrenia And As Adjunctive Therapy For The Treatment Of Major Depressive Disorder 7/14/2014 8:24:21 AM
H. Lundbeck A/S (LUN.CO)'s Late Stage Trials For Stroke Failed To Meet Primary Endpoint 6/27/2014 8:41:52 AM
12345678910